1,937
Views
7
CrossRef citations to date
0
Altmetric
Journal Club

Ibrutinib’s off-target mechanism: cause for dose optimization

ORCID Icon, &
Pages 529-531 | Received 14 Apr 2021, Accepted 24 Aug 2021, Published online: 10 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dan Jiang, Zaiwei Song, Yang Hu, Fei Dong & Rongsheng Zhao. (2022) Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology 15:8, pages 987-996.
Read now

Articles from other publishers (6)

Hyun-ju Lee & Hyang-Sook Hoe. (2023) Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease. Neural Regeneration Research 18:10, pages 2194.
Crossref
Huanan Rao, Xiaominting Song, Jieting Lei, Peng Lu, Guiying Zhao, Xin Kang, Duanna Zhang, Tingrui Zhang, Yali Ren, Cheng Peng, Yuzhi Li, Jin Pei & Zhixing Cao. (2022) Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. International Journal of Molecular Sciences 23:21, pages 13478.
Crossref
Tingyu Cao, Zengguang Wang & Xiaodong Zhu. (2022) The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System. Journal of Inflammation Research Volume 15, pages 6427-6438.
Crossref
Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei & Xiawei Wei. (2022) BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology 15:1.
Crossref
Gellért Balázs Karvaly, István Vincze, Alexandra Balogh, Zoltán Köllő, Csaba Bödör & Barna Vásárhelyi. (2022) A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib. Molecules 27:15, pages 4766.
Crossref
Fansheng Ran, Yun Liu, Chen Wang, Zhongyuan Xu, Yanan Zhang, Yang Liu, Guisen Zhao & Yong Ling. (2022) Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. European Journal of Medicinal Chemistry 229, pages 114009.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.